EVLV posted 45% Q1 revenue growth, raised 2026 guidance, and still trades at a discount because investors do not fully trust the story yet. Here is the bull case, the bear case, and the price range that still works.
This CDNA stock analysis gets interesting fast: CareDx is a transplant diagnostics company that just put up $380 million in 2025 revenue, up 14% year over year, guided to $420 million to $444 million for 2026, and still trades at roughly 2.7 times sales. For a company with category leadership, real profitability, and an earnings …
Small-cap promotion trap checklist is the phrase I wish more retail investors searched before they chased the latest “hidden gem” in a Telegram room. In 2026, the scam is not always a pink-sheet boiler room anymore. Sometimes it looks like a slick Substack thread, a Discord callout, or a social feed full of screenshots that …
Serve Robotics at a Glance Serve Robotics (NASDAQ: SERV) builds sidewalk delivery robots. Spun off from Uber in 2021, the company now operates 2,000 robots across 20 cities and 6 metro areas. Revenue is tiny — $2.7 million in all of 2025. But the 2026 revenue guide just jumped to $26 million. That’s a 10x …
AbCellera looks cheap for a reason, but the setup is finally getting interesting. ABCL stock analysis in April 2026 comes down to three facts: revenue snapped back to $75.1 million in 2025, the company still has roughly $700 million of available liquidity, and lead menopause program ABCL635 has a real catalyst window with Phase 1 …
CDNL stock analysis 2026: Cardinal Infrastructure is growing fast enough to get your attention, but the stock has already run hard enough that you need to be careful. Full-year 2025 revenue jumped 45% to $456.0 million, backlog reached a record $682 million, and 2026 guidance implies another huge step up. The problem is simpler: this …
Is FIRE dead in 2026? No. But the easy version of FIRE is. For most people chasing financial independence, the math got harder over the last few years. Stocks are not cheap, healthcare is still a mess before Medicare, and Morningstar’s latest research says a new retiree who wants inflation-adjusted spending over 30 years should …
Bakkt has tokenization upside, but revenue fell 32% and dilution remains a risk. Here is the bull case, bear case, catalysts, and price framework.
NCNO stock analysis for 2026: strong ACV growth and improving profitability, but valuation and execution risks still matter.
PAHC stock analysis after a strong quarter: real numbers on revenue, EPS, debt, valuation, and whether the rally still has upside.